Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181512 | 0.70 | F2 (0.71) | F2ALDH1A1IKBKBEPHX2KDM4E | |
| SCHEMBL6978676 | 0.69 | F2 (0.44) | F2ALDH1A1IKBKBEPHX2GAA | |
| SCHEMBL11160378 | 0.69 | F2 (0.58) | F2ALDH1A1IKBKBEPHX2GAA | |
| SCHEMBL22652241 | 0.68 | F2 (0.52) | F2ALDH1A1IKBKBEPHX2GAA | |
| SCHEMBL6614850 | 0.67 | F2 (0.56) | F2ALDH1A1IKBKBEPHX2HTT | |
| SCHEMBL279675 | 0.65 | — | — | |
| SCHEMBL4638546 | 0.63 | F2 (0.46) | F2ALDH1A1IKBKBEPHX2LMNA | |
| SCHEMBL6828047 | 0.62 | F2 (0.60) | F2ALDH1A1IKBKBEPHX2KDM4E | |
| SCHEMBL92875 | 0.62 | — | — | |
| SCHEMBL2424445 | 0.62 | DAO (0.60) | F2ALDH1A1IKBKBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |